Threshold Pharmaceuticals
27
0
0
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
22.2%
6 terminated/withdrawn out of 27 trials
71.4%
-15.1% vs industry average
15%
4 trials in Phase 3/4
40%
6 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (27)
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
Role: collaborator
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Role: collaborator
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Role: collaborator
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Role: collaborator
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Role: collaborator
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Role: collaborator
Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer
Role: collaborator
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Role: lead
Dose Escalation Study of Pazopanib Plus TH-302
Role: collaborator
SARC021C: A Continuation Study of TH-CR-406/SARC021
Role: collaborator
A Phase 1 TH-302 Mass Balance Trial
Role: collaborator
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Role: lead
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Role: lead
A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
Role: lead
Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.
Role: collaborator
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Role: lead
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
Role: lead
Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma
Role: collaborator
TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma
Role: collaborator
Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
Role: lead